Company intelligence / Profile preview

Kantify

Brussels, Belgium

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Kantify has demonstrated the ability of its AI platform, Sapian, to rapidly identify and validate first-in-class drug candidates for hard-to-treat conditions, with published preclinical results such as inhibition of tumor growth in prostate cancer models and discovery of novel ion channel activators[1][2].

Therapeutic areas: CardiovascularOncologyNeurology
Modalities: Small moleculeTargeted protein degrader
Industry: Biotech

Drug pipeline

15 assets

KAN-ONCO-01

Preclinical

14 more assets in the full pipeline.

Request access →

Partnerships

Johns Hopkins School of MedicineInstitut du Thorax (Nantes)AFM-TéléthonEuropean Union (EU funding through Project James)

Beyond the preview

Go deeper on Kantify.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kantify.

Explore the full profile